HANGZHOU and SHAOXING, China, July 30, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that its all-oral HCV treatment has been approved for marketing in China by National Medical Products Administration (NMPA). The Company's all-oral HCV treatment (RDV/DNV...
from PR Newswire: https://ift.tt/30bZaqj
No comments:
Post a Comment